Skip to main content

Table 3 Effect of tapering TNFi on the achievement of consecutive BASDAI50 response in the 1-year interval

From: Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study

 

Univariable modelOR (95% CI) (n = 757–776)

Baseline model*OR (95% CI) (n = 748)

Longitudinal modelOR (95% CI) (n = 748)

Baseline variable

 Age, 10 years

0.81 (0.72–0.91)

0.83 (0.72–0.95)

0.83 (0.73–0.94)

 Female sex

0.80 (0.56–1.13)

 Disease duration, 10 years

0.69 (0.55–0.85)

0.89 (0.67–1.17)

0.89 (0.68–1.17)

 Obesity (BMI ≥ 25)

0.88 (0.64–1.20)

 Ever-smokers

0.89 (0.67–1.19)

 Positive HLA-B27 (vs. negative)

1.69 (1.04–2.74)

1.50 (0.83–2.71)

1.47 (0.84–2.56)

 AS (vs. nr-axSpA)

0.77 (0.48–1.21)

 TNFi naïve

1.75 (1.26–2.43)

1.49 (1.01–2.20)

1.44 (0.98–2.10)

 Baseline BASDAI, unit

1.64 (1.52–1.78)

1.61 (1.48–1.75)

1.93 (1.72–2.16)

 Baseline CRP, mg/dL

1.21 (1.10–1.33)

1.13 (1.04–1.23)

1.13 (1.04–1.22)

Longitudinal variable

 Follow-up time (vs. interval in the 1-year follow-up)

Reference

Reference

 Interval in the 2-year follow-up

0.99 (0.81–1.20)

0.52 (0.35–0.77)

 Interval in the 3-year follow-up

0.60 (0.46–0.79)

0.27 (0.16–0.45)

 BASDAIt − 1, unit

1.12 (1.08–1.15)

0.78 (0.70–0.89)

 CRPt − 1, mg/dL

1.11 (1.04–1.18)

1.01 (0.94–1.08)

 Concomitant NSAID use during the interval

0.80 (0.60–1.07)

 Concomitant sulfasalazine use during the interval

0.69 (0.32–1.47)

 Concomitant MTX use during the interval

1.04 (0.49–2.24)

Group according to the interval DQ

 Control group (DQ = 100)

Reference

Reference

Reference

 Mild-tapering group (50 ≤ DQ < 100)

0.93 (0.73–1.20)

0.94 (0.70–1.26)

1.03 (0.61–1.74)

 Heavy-tapering group (DQ < 50)

0.80 (0.43–1.51)

0.82 (0.34–1.97)

1.09 (0.26–4.55)

QIC of the model

 

1367.597

1317.502

  1. AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Activity Index, BMI body mass index, CI confidence interval, CRP C-reactive protein, DQ dose quotient, HLA human leukocyte antigen, MTX methotrexate, nr-axSpA non-radiographic axial spondyloarthritis, NSAID non-steroidal anti-inflammatory drug, OR odds ratio, QIC quasi-likelihood under the independence model criterion, TNFi tumor necrosis factor inhibitor
  2. *The model was adjusted for baseline clinical factors showing a relevant association (P < 0.2) with the outcome in the univariable model
  3. Not included in the model
  4. Not included in the model because its association with the outcome was not relevant (P ≥ 0.2)
  5. The model was adjusted for covariates in the baseline model and longitudinal factors with a relevant association (P < 0.2) with the outcome in the univariable model